Cardinal Health, Inc. vs Hyundai Motor Company: Strategic Comparison

This in-depth comparison examines Cardinal Health, Inc. and Hyundai Motor Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cardinal Health, Inc. on its own, evaluating Hyundai Motor Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cardinal Health, Inc. and Hyundai Motor Company is widest.

On the headline numbers, Cardinal Health, Inc. reports annual revenue of $254.2B against ~$132.2B for Hyundai Motor Company, while their respective market capitalizations stand at $56.0B and $52.0B. Cardinal Health, Inc. is headquartered in United States and Hyundai Motor Company in South Korea, and those different home markets shape how each company competes.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

Hyundai Motor Company: Hyundai Motor Company is South Korea's largest automaker and the flagship of Hyundai Motor Group, which also includes Kia, Hyundai Mobis, Hyundai Steel and Hyundai Glovis. It sells Hyundai and Genesis vehicles in more than 190 countries, runs major plants in Ulsan, Alabama, Georgia, India, the Czech Republic, Turkey, Brazil and Indonesia, and employs about 123,000 people. Once known for cheap, unreliable cars, Hyundai rebuilt its reputation with a 10-year/100,000-mile U.S. powertrain warranty in 1998, sharper design and award-winning EVs. Today it is a hybrid and SUV-led business with growing bets on EVs, hydrogen and robotics.

Cardinal Health, Inc. and Hyundai Motor Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cardinal Health, Inc. and Hyundai Motor Company.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

Hyundai Motor Company business model: Hyundai earns most of its revenue from wholesale vehicle sales to dealers and distributors across North America, Korea, Europe, India and emerging markets. Three layers sit on top of that core: the Genesis luxury brand, which lifts average transaction prices; a finance division (Hyundai Capital and Hyundai Capital America) that earns interest and lease income on vehicle loans; and after-sales parts and service. Hyundai shares platforms, powertrains and R&D with Kia, in which it holds about one-third of the shares, and buys modules, steel, software and logistics from group affiliates such as Hyundai Mobis, Hyundai Steel, Hyundai AutoEver and Hyundai Glovis. That group structure spreads development costs over roughly 7 million combined vehicles a year.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cardinal Health, Inc. stack up against those of Hyundai Motor Company.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

Hyundai Motor Company competitive advantage: Hyundai's edge is breadth plus speed. It can offer gasoline, hybrid, plug-in, battery-electric and hydrogen versions of key models, which matters as EV demand stalls in some markets and hybrids take more than a quarter of its U.S. sales. Platform sharing with Kia and in-house sourcing through Hyundai Mobis, Hyundai Steel and Hyundai Glovis give it scale and supply control, and its 800-volt E-GMP platform made the Ioniq 5 and Ioniq 6 back-to-back World Car of the Year winners in 2022 and 2023. Growing U.S. production at Alabama and the Georgia Metaplant is turning tariff exposure into a localisation advantage.

Future prospects matter as much as current results. The growth strategies below explain how Cardinal Health, Inc. and Hyundai Motor Company each plan to expand from here.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

Hyundai Motor Company growth strategy: Hyundai's growth strategy rests on four moves: localising production in the United States, India and other big markets to avoid tariffs; expanding hybrids across its range while keeping EV investment flexible; pushing Genesis higher in luxury; and building software, autonomous driving and robotics. In the U.S. the $26 billion plan through 2028 includes raising Georgia Metaplant capacity, a new steel plant in Louisiana with Hyundai Steel, and the Hyundai-LG battery plant that opened in 2026 after delays. In India, Hyundai Motor India listed on Indian exchanges in October 2024 in what was then the country's largest IPO. In July 2026 the group agreed to buy SoftBank's remaining stake in Boston Dynamics, making it a wholly owned subsidiary.

A closer look at the financial trajectory of Cardinal Health, Inc. and Hyundai Motor Company rounds out the comparison.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.

Hyundai Motor Company: Hyundai's revenue has grown every year since 2020, from ~$83.5 billion (KRW 117.6 trillion) in 2021 to ~$132 billion (KRW 186.25 trillion) in 2025. Profit peaked in 2023 and 2024, when operating profit topped ~$9.94 billion (KRW 14 trillion) on a rich SUV mix and a weak won. In 2025 operating profit fell 19.5% to ~$8.14 billion (KRW 11.47 trillion) and net profit fell 21.7% to ~$7.36 billion (KRW 10.36 trillion), mostly because of U.S. tariffs. Q2 2026 revenue was a record ~$34.9 billion (KRW 49.22 trillion), up 1.9%, but operating profit dropped 20.8% to ~$2.02 billion (KRW 2.85 trillion), leaving H1 2026 operating profit at ~$3.81 billion (KRW 5.37 trillion) against ~$5.14 billion (KRW 7.24 trillion) a year earlier. The company paid a total 2025 dividend of KRW 10,000 per share, and its 2026 guidance calls for 1-2% revenue growth and a 6.3-7.3% operating margin, which its CFO said in July it may miss on volume.